Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Average Rating of “Moderate Buy” by Analysts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has earned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $19.5714.

A number of equities analysts recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Guggenheim reissued a “buy” rating and issued a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Finally, Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research note on Friday, February 6th.

Adaptive Biotechnologies Price Performance

ADPT stock opened at $12.96 on Friday. Adaptive Biotechnologies has a 1 year low of $8.50 and a 1 year high of $20.76. The company has a market cap of $2.07 billion, a P/E ratio of -39.27 and a beta of 2.16. The firm has a 50-day moving average of $13.83 and a 200 day moving average of $15.67.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same period in the prior year, the firm earned ($0.20) earnings per share. Adaptive Biotechnologies’s revenue was up 35.1% on a year-over-year basis. On average, equities research analysts expect that Adaptive Biotechnologies will post -0.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 470,266 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $6,193,403.22. Following the completion of the transaction, the insider owned 1,522,058 shares of the company’s stock, valued at approximately $20,045,503.86. This trade represents a 23.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Julie Rubinstein sold 141,583 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.29, for a total transaction of $1,881,638.07. Following the transaction, the chief operating officer directly owned 516,610 shares of the company’s stock, valued at $6,865,746.90. This represents a 21.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 2,417,168 shares of company stock valued at $34,153,000. 5.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. increased its stake in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after acquiring an additional 3,299,635 shares in the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $65,942,000. Geode Capital Management LLC increased its position in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after acquiring an additional 110,825 shares in the last quarter. Finally, State Street Corp increased its position in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after acquiring an additional 102,362 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.